পদ্ধতির তুলনা করুন
নির্বাচিত পদ্ধতিগুলো পাশাপাশি পর্যালোচনা করুন; যে সারিগুলোয় পার্থক্য আছে সেগুলো চিহ্নিত করা হয়।
| ঝুঁকি-সমন্বিত ফেজ I ক্লিনিকাল ট্রায়াল× | ডোজ-প্রতিক্রিয়া বিশ্লেষণ× | |
|---|---|---|
| ক্ষেত্র | মহামারীবিদ্যা | মহামারীবিদ্যা |
| পরিবার | Process / pipeline | Process / pipeline |
| উদ্ভবের বছর≠ | 1990s–2000s | Conceptual roots 16th century; modern epidemiological application mid-20th century |
| প্রবর্তক≠ | Evolved from the Continual Reassessment Method (O'Quigley et al., 1990) extended with patient-level risk covariates | Paracelsus (conceptual foundation); formalized by John Snow and later Bradford Hill |
| ধরন≠ | Interventional clinical trial design | Quantitative analytical method |
| মৌলিক উৎস≠ | Iasonos, A., Wilton, A. S., & Gonen, M. (2008). A review of stochastic dose-finding methods. Statistics in Medicine, 27(25), 5031–5046. link ↗ | Rothman, K. J., Greenland, S., & Lash, T. L. (2008). Modern Epidemiology (3rd ed.). Lippincott Williams & Wilkins. ISBN: 978-0781755641 |
| অপর নাম | risk-stratified Phase I trial, risk-adaptive dose-escalation study, covariate-adjusted Phase I study, risk-based dose-finding trial | exposure-response analysis, concentration-response modeling, dose-response modeling, DRA |
| সম্পর্কিত≠ | 5 | 4 |
| সারসংক্ষেপ≠ | A risk-adjusted Phase I clinical trial is a first-in-human or dose-finding study that explicitly incorporates patient-level risk covariates — such as organ function, prior therapy, or genetic markers — into the dose-escalation model. Rather than treating all enrolled participants as homogeneous, the design accounts for individual differences in tolerance, allowing the recommended dose to vary by risk stratum. This approach is especially common in oncology, where patients with impaired renal function or heavily pre-treated disease may tolerate lower doses than the broader population. | Dose-response analysis quantifies the relationship between the magnitude of an exposure (the dose) and the probability or rate of an outcome (the response). It is a core analytical strategy in epidemiology and toxicology, providing evidence that increasing exposure systematically increases — or decreases — the risk of disease. A demonstrated dose-response gradient is one of Bradford Hill's classic criteria supporting causal inference. |
| ScholarGateডেটাসেট ↗ |
|
|